China’s procurement policy lowered the cost barrier for childhood leukemia therapy
Childhood leukemia treatment depends on sustained access to tyrosine kinase inhibitors, yet these drugs can place a heavy financial strain on families and hospitals. In China, the National Volume-Based Procurement policy changed that equation for at least some medicines in this class, most clearly for imatinib, which was included in the policy. Analysis of procurement data from children’s hospitals between January 2019 and December 2020 showed that the policy altered both how much drug was bought and how spending was distributed across product types.
The study focused on three TKIs used in pediatric leukemia care: imatinib, nilotinib, and dasatinib. Investigators used an interrupted time series design to evaluate three linked outcomes: affordability, measured as the monthly cost-to-wage ratio; procurement volume, measured in defined daily doses; and total expenditure. This approach is useful for policy analysis because it examines whether a structural change in the market is followed by a measurable shift in purchasing behavior, rather than relying on a one-time before-and-after comparison.
For imatinib, the clearest signal emerged after implementation of the procurement policy. Procurement volume increased significantly, and expenditure rose as well, both with statistically significant trends after policy introduction. The increase in volume for bid-winning generics was especially pronounced. In practical terms, hospitals did not simply spend less and buy the same amount; they bought more of the lower-priced product that had won the procurement bid, and that changed the composition of TKI spending across the system.
One sentence captures the central shift: lower prices translated into greater use of the procured generic.
Generic substitution reshaped spending patterns in pediatric hospitals
The mechanism is straightforward. When a centralized purchasing system secures lower prices for a bid-winning generic, hospitals can stretch a fixed budget across more treatment courses, and families face a smaller out-of-pocket burden when medication costs are linked to the broader procurement environment. In a disease such as childhood leukemia, where therapy may extend over long periods and adherence matters, even modest reductions in drug cost can influence whether treatment remains reachable and continuous.
The expenditure structure for TKI drugs changed gradually after the policy took effect. The proportion of spending on bid-winning generic drugs increased over time, indicating a steady shift in purchasing behavior rather than an abrupt one-day replacement of originator products. This matters because medication affordability is not only about the unit price of a tablet or capsule; it is also about whether the health system is organized to favor sustained uptake of the lower-cost option. A procurement policy can therefore alter access by changing the default market pathway for hospitals, pharmacies, and prescribers.
The findings were not uniform across all TKIs. The strongest evidence of policy influence appeared for imatinib, the agent included in the NVBP framework. For the broader TKI class, the effect depended on policy coverage and product status, which is exactly what one would expect from a procurement intervention rather than a pharmacologic class effect. Nilotinib and dasatinib were part of the analysis, but the policy signal was most evident where the drug was actually captured by the procurement mechanism.
Affordability, as measured by the monthly cost-to-wage ratio, was one of the study’s core endpoints because it links market price to household earning power. That ratio is especially relevant in pediatric oncology, where caregivers often absorb indirect costs alongside the medication bill itself. Even when a drug is clinically indispensable, a high cost-to-wage ratio can function as a silent barrier to timely treatment initiation and continuation. By improving the affordability profile of imatinib, the policy addresses a point where economics and adherence intersect.
Policy gains were real, but pediatric needs are still not fully met
The results support the idea that China’s National Volume-Based Procurement policy can improve access to TKIs in childhood leukemia by driving generic substitution and optimizing expenditure structure. The spending shift toward bid-winning generic drugs suggests that procurement policy can influence therapeutic availability in a way that is immediately visible in hospital purchasing data. For a family navigating leukemia treatment, that kind of change can mean fewer financial interruptions in care.
Still, the analysis also points to the limits of a one-size-fits-all procurement model in pediatrics. Children are not simply small adults, and pediatric oncology requires attention to dosing flexibility, formulation availability, and the narrower market that often surrounds childhood diseases. A procurement policy designed for broad adult use may improve affordability while still leaving pediatric-specific needs only partly addressed. The study’s conclusion reflects that reality: the policy improved affordability and promoted generic substitution, but further refinement tailored to children remains necessary.
The clinical implication is not complicated. When a public purchasing policy reduces the cost of a key leukemia drug, hospitals buy more of it and the expenditure mix shifts toward the lower-cost product. The unanswered operational question is how best to extend that benefit across the full pediatric leukemia drug set without compromising access to agents that are not yet covered by the same procurement structure. The data from children’s hospitals show one drug-level success clearly, while also revealing how dependent access remains on the details of policy design.